Ballentine Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $527K | Sell |
1,617
-8
| -0.5% | -$2.61K | 0.01% | 465 |
|
|
2025
Q1 | $439K | Buy |
1,625
+52
| +3% | +$14K | 0.01% | 487 |
|
|
2024
Q4 | $370K | Buy |
1,573
+39
| +3% | +$9.18K | 0.01% | 515 |
|
|
2024
Q3 | $422K | Buy |
1,534
+145
| +10% | +$39.9K | 0.01% | 469 |
|
|
2024
Q2 | $338K | Buy |
+1,389
| New | +$338K | 0.01% | 523 |
|
|
2024
Q1 | – | Sell |
-1,221
| Closed | -$234K | – | 742 |
|
|
2023
Q4 | $234K | Buy |
+1,221
| New | +$234K | ﹤0.01% | 584 |
|